The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study

BackgroundAlthough recent guidelines recommend that tapering of biologic disease-modifying anti-rheumatic drugs (bDMARDs) can be considered in patients with rheumatoid arthritis (RA), there has been little evidence supporting the strategy during the non-tumor necrosis factor inhibitor treatment. Thi...

Full description

Bibliographic Details
Main Authors: Jun Won Park, Min Jung Kim, Hyoun-Ah Kim, Jin Hyun Kim, Eun Bong Lee, Kichul Shin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Medicine
Subjects:
rheumatoid arthritis
tocilizumab
dose tapering
treat-to-target
bDMARD therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.839206/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.839206/full

Similar Items